Newsletter Subject

FDA Advisors Not Convinced Once-Weekly Insulin Is Safe in Type 1 Diabetes

From

medpagetoday.com

Email Address

daily.headlines@broadcaster3.medpagetoday.com

Sent On

Fri, May 24, 2024 10:47 PM

Email Preheader Text

Daily Headlines Friday, May 24, 2024 Today's Top Stories for {NAME} THE BREAK ROOM CME SPOTLIGHT THE

[MEDPAGE TODAY]( Daily Headlines Friday, May 24, 2024 Today's Top Stories for {NAME} [ENDOCRINOLOGY]( [FDA Advisors Not Convinced Once-Weekly Insulin Is Safe in Type 1 Diabetes]( [INFECTIOUS DISEASE]( [CDC Prepping for 'Possibility of Increased Risk to Human Health' From Bird Flu]( [INFECTIOUS DISEASE]( [Antimicrobial Resistance Must Be Addressed Now, Global Experts Warn]( THE BREAK ROOM [Spell Check-Up: Try to Pass This Spelling Quiz]( CME SPOTLIGHT [Beyond Transfusions: New and Emerging Therapies for Beta Thalassemia]( [MEETING COVERAGE]( [HPV Vaccination Reduces Risk of Multiple Types of Cancer in Men and Women]( [MEETING COVERAGE]( [Most Women Can Have Successful Pregnancies After Breast Cancer Treatment]( THE BREAK ROOM [Play Today’s Wordosis]( ADVERTISEMENT [MEETING COVERAGE]( [Gallbladder Cancer Rates Stable or Down, Except in Black Patients]( CME SPOTLIGHT [Navigating the Nuances of von Hippel-Lindau (VHL) Disease Care: A Clinical Challenge in Treatment and Management]( [MEETING COVERAGE]( [Estrogen-Only Therapy for Menopausal Symptoms Increases Ovarian Cancer Risk]( [GASTROENTEROLOGY]( [Blood in Stool, Abdominal Pain Top Red Flags for Early-Onset Colorectal Cancer]( [AAD READING ROOM]( [Oral IL-23 Inhibitor Shows Promise for Moderate-to-Severe Psoriasis in New Trial]( THE BREAK ROOM [Wordectomy: Guess Today’s Medical Condition]( CME SPOTLIGHT [Adjuvant Endocrine Therapy in HR+ Breast Cancer: Enhancing Quality Care and Patient Outcomes]( [PUBLIC HEALTH & POLICY]( [Dying Ex-Doctor Leaves Prison 2 Years After Pardon for Killing His Dad]( [GASTROENTEROLOGY]( [Blood Test for Colon Cancer Screening Secures FDA Panel's Blessing]( [ASCO READING ROOM]( [All Over the Map? Mechanisms of ICI Acquired Resistance in NSCLC]( CME SPOTLIGHT [Empowering Historically Underrepresented Patients: Overcoming Healthcare Disparities in Multiple Myeloma]( [ASCO READING ROOM]( [From Robust Response to Rapid Resistance]( [ONCOLOGY/HEMATOLOGY]( [Ignoring Colonoscopy Advice; Inflamed Tongue, Then Cancer; Acupuncture for Dry Mouth]( [RHEUMATOLOGY]( [Study Confirms: No Great Options for Treating VEXAS]( CME SPOTLIGHT [Positioning CAR T-Cell Therapy in the CLL Treatment Landscape]( [MEETING COVERAGE]( [BTK Inhibitor Likely to Get a Pass to Phase III in Uncontrolled Asthma]( [PERSPECTIVES]( [Suicide Research Must Consider Both the 'How' and the 'Why']( [ENDOCRINOLOGY]( [Ozempic Protects Kidneys, Boosts Survival in Diabetes Patients With CKD]( CME SPOTLIGHT [Employing Collaborative Care Strategies for the Management of Pediatric Patients With Hodgkin Lymphoma]( Industry Clinic AD INSIGHTS [Recognizing Racial Disparities Impacting Rare Kidney Disease Patients]( # Weekly Survey [Will Measles Be Endemic Again?]( A child in Canada recently [died from measles](, while cases are [surging in the U.K.]( and [increasing in the U.S.]( -- all as vaccination rates are dropping[VOTE >]( Meeting Coverage Can't get away? MedPage Today brings you extensive coverage of more than 80 meetings in a wide range of specialties. [SEE ALL STORIES >]( Got a news tip? MedPage Today offers several ways to provide information to our journalists securely and confidentially. [LEARN MORE >]( [EVERYDAY HEALTH]( © 2024 MedPage Today, LLC. MedPage Today is among the federally registered trademarks of MedPage Today, LLC, and may not be used by third parties without explicit permission. You have received this email because you have registered to receive emails at www.medpagetoday.com, with the email address: {EMAIL} [Manage Email Preferences]( | [Unsubscribe](lst=NL_Daily_DHE?xid=nl_mpt_DHE_2024-05-24&eun=g1020308d0r) | [Terms of Use]( | [Privacy Policy]( Technical Questions: feedback@medpagetoday.com 114 5th Avenue, 15th Floor New York, NY 10011

Marketing emails from medpagetoday.com

View More
Sent On

08/12/2024

Sent On

08/11/2024

Sent On

07/11/2024

Sent On

07/11/2024

Sent On

06/11/2024

Sent On

04/11/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2025 SimilarMail.